Accuitis Overview
Latest Deal Type
Later Stage VC
Accuitis General Information
Description
Developer and marketer of pharmaceuticals intended for dermatological diseases. The company's therapy contains proteasome inhibitor for the treatment of rosacea and other topical skin diseases, providing patients drugs for the treatment of rosacea.
Accuitis Timeline
Want to dig into this profile?
We’ll help you find what you need
Learn more
Accuitis Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 3. Later Stage VC |
31-Aug-2018 |
$1M |
00.000 |
|
Completed |
Generating Revenue |
| 2. Later Stage VC |
05-Sep-2017 |
00.000 |
00.000 |
|
Completed |
Startup |
| 1. Grant |
|
|
|
|
Completed |
Startup |
Accuitis Executive Team (4)
| Name |
Title |
Board Seat |
Contact Info |
| Richard Coulon |
Co-Founder, President Chief Executive Officer & Board Member |
|
|
| Michael Shippel |
Chief Financial Officer & Board Member |
|
|
| Mark Jackson MD |
Medical Consultant |
|
|
| Jack Arbiser Ph.D |
Co-Founder & Chief Innovation Officer |
|
|